CoChat
Sign Up
Cited by 66

Cellular pathways of recombinant adeno-associated virus production for gene therapy

Sha, Sha, Maloney, Andrew J., Katsikis, Georgios, Nguyen, Tam N.T., Neufeld, Caleb, Wolfrum, Jacqueline, Barone, Paul W., Springs, Stacy L. +3 more·2021·Biotechnology Advances
DOI 10.1016/j.biotechadv.2021.107764
Open this paper in CoChat — free account

Abstract

Recombinant adeno-associated viruses (rAAVs) are among the most important vectors for in vivo gene therapies. With the rapid development of gene therapy, current rAAV manufacturing capacity faces a challenge to meet the emerging demand for these therapies in the future. To examine the bottlenecks in rAAV production during cell culture, we focus here on an analysis of cellular pathways of rAAV production, based on an overview of assembly mechanisms first in the wild-type (wt) AAV replication and then in the common methods of rAAV production. The differences analyzed between the wild-type and recombinant systems provide insights into the mechanistic differences that may correlate with viral productivity. Based on these analyses, we identify potential barriers to high productivity of rAAV and discuss future directions for improvement to meet the emerging needs set by the growth of rAAV-based therapy and the needs of patients.

Integrity signals

Registry

Crossref · 10.1016/j.biotechadv.2021.107764

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • No unified mechanistic framework currently captures AdV, AAV, and LV processes within the same HEK293 host using a consistent mathematical structure that allows cross platform parameterization with minimal structural modification.

    “Despite these contributions, no unified mechanistic framework currently captures AdV, AAV, and LV processes within the same HEK293 host using a consistent mathematical structure that allows cross platform parameterization with minimal structural modification [21, 22].”

    From Mechanistic model for HEK293 viral vector processes and its application in a digital shadow framework (2026) · cites this paper as [21]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sha, S., Maloney, A. J., Katsikis, G., Nguyen, T. N. T., Neufeld, C., Wolfrum, J., Barone, P. W., Springs, S. L., Manalis, S. R., Sinskey, A. J., & Braatz, R. D.
Venue
Biotechnology Advances
Publisher
Elsevier BV
Published
2021-07
Volume
49
Pages
107764
ISSN
0734-9750
DOI
10.1016/j.biotechadv.2021.107764
Cited by
66
References
14
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review